Aeon Global Health 10-Q 26 Jan 18 2018 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Dec. 31, 2017	Jan. 19, 2018
Document Information [Line Items]
Entity Registrant Name	AUTHENTIDATE HOLDING CORP
Entity Central Index Key	885,074
Trading Symbol	adat
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		7,249,370
Document Type	10-Q
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Dec. 31, 2017	Jun. 30, 2017
Current assets
Cash and cash equivalents	$ 357,165	$ 1,121,763
Restricted cash		120,695
Accounts receivable, net	2,467,935	1,020,988
Inventory, net	397,569	347,750
Prepaid expenses and other current assets	38,729	58,711
Total current assets	3,261,398	2,669,907
Property and equipment, net	1,780,123	2,203,543
Other assets
Security deposits	10,211	10,211
Deferred tax asset	7,357,436	11,848,017
Total assets	12,409,168	16,731,678
Current liabilities
Accounts payable	1,269,454	2,177,722
Accrued expenses	2,493,374	2,168,090
Accrued commissions	855,424	427,627
Accrued dividends	816,377	644,979
Deferred rent	170,483	141,833
Related party notes payable	2,545,199	2,545,199
Derivative liabilities	185,176	551,040
Total current liabilities	8,335,487	8,656,490
Deferred rent	90,000	45,000
Total liabilities	8,425,487	8,701,490
Commitments and contingencies
Shareholders' equity
Preferred stock, $.10 par value; 5,000,000 shares authorized, Series D, 605,000 shares and Series E 25,000 shares issued and outstanding at December 31, 2017 , and June 30, 2017, respectively	63,000	63,000
Common stock, $.001 par value; 190,000,000 shares authorized, 7,249,370 shares issued and outstanding on December 31, 2017, and June 30, 2017 , respectively	20,508	8,938
Additional paid-in capital	44,530,041	44,307,479
(Accumulated deficit)	(40,629,868)	(36,349,229)
Total shareholders' equity	3,983,681	8,030,188
Total liabilities and shareholders' equity	$ 12,409,168	$ 16,731,678

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Dec. 31, 2017	Jun. 30, 2017
Preferred stock, par value (in dollars per share)	$ 0.10	$ 0.10
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	190,000,000	190,000,000
Common stock, shares issued (in shares)	7,249,370	7,249,370
Common stock, shares outstanding (in shares)	7,249,370	7,249,370
Series D Convertible Preferred Stock [Member]
Preferred stock, shares issued (in shares)	605,000	605,000
Preferred stock, shares outstanding (in shares)	605,000	605,000
Series E Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 30	$ 30
Preferred stock, shares issued (in shares)	25,000	25,000
Preferred stock, shares outstanding (in shares)	25,000	25,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Net revenues
Fees for services	$ 5,278,042	$ 4,565,435	$ 8,388,424	$ 10,256,731
Hosted software services	248,530	311,671	491,550	658,605
Telehealth products and services	4,650	9,707	9,300	21,552
Total net revenues	5,531,222	4,886,813	8,889,274	10,936,888
Operating expenses
Cost of revenues	888,541	951,668	2,017,117	2,195,838
Write down of inventory			0	237,674
Selling, general and administrative	3,042,771	4,204,114	6,153,936	7,727,165
Share based compensation	21,111	89,526	51,159	148,476
Depreciation and amortization	200,837	394,484	423,421	803,147
Total operating expenses	4,153,261	5,639,792	8,645,633	10,874,626
Operating income (loss)	1,377,961	(752,979)	243,641	62,262
Other (expense) income
Interest	(37,013)	(92,175)	(64,362)	(370,768)
Change in fair value of derivative liabilities	292,573	621,820	365,864	135,601
Other	(124,149)		(162,294)
Total other (expense) income	131,411	529,645	139,208	(235,167)
Income (loss) before provision for income taxes	1,509,372	(223,334)	382,849	(172,905)
Provision for income taxes	(4,493,239)	(45,404)	(4,493,239)
Net loss	(2,983,867)	(268,738)	(4,110,390)	(172,905)
Less: preferred dividends	(85,699)	(100,624)	(170,249)	(201,248)
Net loss available to common shareholders	$ (3,069,566)	$ (369,362)	$ (4,280,639)	$ (374,153)
Loss per share:
Basic loss per common share (in dollars per share)	$ (0.42)	$ (0.06)	$ (0.59)	$ (0.06)
Diluted loss per common share (in dollars per share)	$ (0.42)	$ (0.06)	$ (0.59)	$ (0.06)
Weighted average number of common shares outstanding:
Basic (in shares)	7,249,370	6,015,053	7,249,370	5,893,655
Diluted (in shares)	7,249,370	6,015,053	7,249,370	5,893,655

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities
Net loss	$ (4,110,390)	$ (172,905)
Adjustments to reconcile net income (loss) to net cash used by operating activities
Impairment of deferred tax asset	4,490,581
Change in fair value of derivative liabilities	(365,864)	(135,601)
Write down of inventory	0	237,674
Depreciation and amortization	423,421	803,147
Deferred taxes
Share based compensation	51,159	148,476
Changes in assets and liabilities
Restricted cash	120,695
Accounts receivable	(1,446,948)	1,067,894
Inventory	(49,819)	(303,637)
Prepaid expenses and other current assets	19,982	49,696
Accounts payable	(650,497)	(1,130,623)
Accrued expenses	325,285	(465,416)
Accrued commissions	427,797	(72,546)
Deferred rent		(4,874)
Net cash provided (used) by operating activities	(764,598)	21,285
Cash flows from investing activities
Purchases of property and equipment		(22,103)
Disposal of fixed assets
Net cash (used in) investing activities		(22,103)
Cash flows from financing activities
Repayments of notes payable		(1,057,811)
Net cash (used in) financing activities		(1,057,811)
Net decrease in cash	(764,598)	(1,058,629)
Cash beginning of period	1,121,763	1,414,706
Cash end of period	357,165	356,077
Supplemental disclosure of cash paid for:
Interest paid	99,005	227,758
Income taxes paid
Non-cash investing and financing activities
Non-cash preferred dividends	137,249	201,248
Earn-out common dividends paid in stock		$ 5,472,598

Note 1 - Description of Busines

Note 1 - Description of Business, Reverse Merger and Liquidity	6 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Description of Business , Reverse Merger and Liquidity Authentidate Holding Corp. ("AHC") and its subsidiaries primarily provides an array of clinical testing services to health care professionals through its wholly-owned subsidiary, Peachstate Health Management, LLC d/b/a AEON Clinical Laboratories ("AEON"). AHC also continues to provide its legacy secure web-based revenue cycle management applications and telehealth products and services that enable healthcare organizations to increase revenues, improve productivity, reduce costs, coordinate care for patients and enhance related administrative and clinical workflows and compliance with regulatory requirements. Web-based services are delivered as Software as a Service (SaaS) to customers interfacing seamlessly with billing, information and records management systems. Reverse Merger On January 27, 2016, ed January 26, 2016, May 31, 2016 December 15, 2016 ( January 27, 2016. four Under accounting principles generally accepted in the United States of America (" U.S. GAAP"), the merger is treated as a "reverse merger" under the purchase method of accounting. The condensed consolidated financial statements reflect the historical results of AEON prior to the completion of the reverse merger since it was determined to be the accounting acquirer, and do not Going Concern As of the filing date of this Quarterly Report on Form 10 $2,545,199 March 20, 2018 $210,000 June 15, 2018 no twelve no not The Company 's capital requirements have been and will continue to be significant and it is expending significant amounts of capital to develop, promote and market its services. The Company's available cash and cash equivalents as of December 31, 2017 $357,000 $5,074 ,000. Nevertheless, our available cash and cash equivalents as of the filing date of this Quarterly Report on Form 10 $1,057,000 $1,300,000. The Company does not We are exploring potential transactions to improve our capital position to ensure we can meet our financing and working capital requirements. We would expect to raise additional funds through obtaining a credit facility from an institutional lender or undertaking private debt financings. Raising additional funds by issuing equity or convertible debt securities may may may may may may may not third no Management has concluded that due to the conditions described above, there is substantial doubt about the entity 's ability to continue as a going concern. We have evaluated the significance of the conditions in relation to our ability to meet our obligations and believe that our current cash balance will provide sufficient capital to continue operations through fiscal 2018. no no

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Basis of Presentation The Company 's condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and following the requirements of the Securities and Exchange Commission ("SEC") for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These interim financial statements have been prepared on the same basis as the Company's annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company's financial information. These interim results are not June 30, 2018 June 30, 2017, 2017 10 The balance sheet as of June 30, 2017 not l statements. Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. Use of Esti mates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most sensitive accounting estimates affecting the financial statements are revenue recognition, the allowance for doubtful accounts, depreciation of long-lived assets, fair value of intangible assets and goodwill, amortization of intangible assets, income taxes and associated deferrals and valuation allowances, commitments and contingencies and measurement of derivative liabilities. Accounts R eceivable, Net Accounts receivable represent customer obligations due under normal trade terms, net of allowance for doubtful accounts. The allowance for doubtful accounts reflects our best estimate of probable losses inherent in the accounts receivable balance. We determine the allowance based on known troubled accounts, historical experience and other currently available evidence. The allowance for doubtful accounts was approximately $887,000 $923,000 December 31, 2017 June 30, 2017, Fair Value Measurements The Company follows ASC 820 10, "Fair Value Measurements and Disclosures" 820 10 820 10 three three 820 10 Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, Level 3 Pricing inputs that are generally unobservable input and not The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lower priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one 3. Revenue Recognition The Company provides laboratory testing services, web-based hosted so ftware services, telehealth products and post contract customer support services. In accordance with Financial Accounting Standards Board (" FASB") Accounting Standards Codification ("ASC") ASC- 605 "Revenue Recognition" third Revenue from laboratory testing services are recognized at the time test results are delivered, net of estimat ed contractual allowances. Third-party reimbursement revenue is estimated based on cash received over a 12 Revenue for hosted software services, telehealth products, and customer support services are recognized when persuasive evidence of an arrangement exists, delivery has occurred, the selling price is fixed and collectability is reasonably assured. Multiple-element arrangements are assessed to determine whether they can be separated into more than one one not Concentrations of Credit Risk The Company maintains its cash in bank deposit acco unts which, at times, may December 31, 2017 June 30, 2017, $119,000 $871,000 not Income Taxes The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in tax laws or rates. The effect on deferred tax assets and liabilities of a change in tax rates will be recognized as income or expense in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. Management considers the likelihood of changes by taxing authorities in its filed income tax returns and recognizes a liability for or discloses potential changes that management believes are more likely than not not Reclassification Certain prior year amounts have been reclassified to conform to the current year presentation. Recent Accounting Pronouncements In May 2014, 2014 09, "Revenue from Contracts with Customers" 606 2014 09" 2014 09, December 15, 2017, December 15, 2016. not July 1, 2018. In August 2014, No. 2014 15, "Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern". one one December 15, 2016 2014 15 10 In July 2015, 2015 11, "Inventory Topic 330 Simplifying the Measurement of Inventory" 2015 11 first 2015 11 December 15, 2016. no not In January 2016, issued ASU 2016 01, "Financial Instruments (Subtopic 825 10 Recognition and Measurements of Financial Assets and Financial Liabilities." 2016 01 may not first 2018. no not In February 2016, d ASU No. 2016 02, "Leases" 12 December 15, 2018, 2016 02 July 1, 2019. In March 2016, No. 2016 09, "Compensation-Stock Compensation (Topic 718 Payment Accounting" December 15, 2016, not not In August 2016, No. 2016 15, "Statement of Cash Flows (Topic 230 July 1, 2018 July 1, 2018. In November 2016, 2016 18, "Restricted Cash" first 2018 July 1, 2018. In May 2017, 2017 09, "Compensation-Stock Compensation (Topic 718 December 15, 2017. July 1, 2018. In July 2017, 2017 11, "Earnings Per Share (Topic 260 480 815 , no no 260 July 1, 2019. In December 2017, unting Bulletin No. 118, 740, Income Taxes December 22, 2017, No. 118 December 22, 2017. No. 118 10 December 31, 2017

Note 3 - Restatement and Correc

Note 3 - Restatement and Correction of Error	6 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Accounting Changes and Error Corrections [Text Block]	3. Restatement and Correction of Error In the fourth June 30, 2017, December 31, 2016 10 June 30, 2017. not The following adjustments were made to the December 31, 2016 AUTHENTIDATE HOLDING CORP CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) As Originally As Originally Reported As Restated Reported As Restated Three Months Three Months Six Months Six Months Ended Ended Ended Ended Dec 31, Dec 31, Dec 31, Dec 31, 2016 Adj 2016 2016 Adj 2016 Net revenues Fees for services $ 4,565,435 $ - $ 4,565,435 $ 10,256,731 $ - $ 10,256,731 Hosted software services 311,671 - 311,671 658,605 - 658,605 Telehealth services 9,707 - 9,707 21,552 - 21,552 Total net revenues 4,886,813 - 4,886,813 10,936,888 - 10,936,888 Operating expenses Cost of revenues 1,128,218 (176,550 ) 951,668 2,295,214 (337,050 ) 1,958,164 Write-down of inventory - - - 237,674 - 237,674 Selling, general and administrative 4,293,640 - 4,293,640 7,875,641 - 7,875,641 Depreciation and amortization 394,484 - 394,484 803,147 - 803,147 Total operating expenses 5,816,342 (176,550 ) 5,639,792 11,211,676 (337,050 ) 10,874,626 Operating income (loss) (929,529 ) 176,550 (752,979 ) (274,788 ) 337,050 62,262 Other (expense) income, net 529,645 - 529,645 (235,167 ) - (235,167 ) Income (loss) before provision for income taxes (399,884 ) 176,550 (223,334 ) (509,955 ) 337,050 (172,905 ) Income tax provision 45,404 - (45,404 ) - - - Net loss $ (445,288 ) $ 176,550 $ (268,738 ) $ (509,955 ) $ 337,050 $ (172,905 ) less: preferred dividends $ (100,624 ) $ - $ (100,624 ) $ (201,248 ) $ - $ (201,248 ) Net loss available to common shareholders $ (545,912 ) $ 176,550 $ (369,362 ) $ (711,203 ) $ 337,050 $ (374,153 ) Loss per share: Basic loss per common share $ (0.09 ) $ 0.03 $ (0.06 ) $ (0.12 ) $ 0.06 $ (0.06 ) Diluted loss per common share $ (0.09 ) $ 0.03 $ (0.06 ) $ (0.12 ) $ 0.06 $ (0.06 ) The followi ng adjustments were made to the December 31, 2016 AUTHENTIDATE HOLDING CORP. CONSOLIDATED STATEMENT OF CASH FLOW As Originally Reported As Restated Six Months Six Months Ended Ended Dec 31, Dec 31, 2016 Adj 2016 Cash Flows from Operating Activities Net Loss $ (509,955 ) $ 337,050 $ (172,905 ) Adjustments to reconcile net loss to cash provided by operating activities Write off of inventory 237,674 - 237,674 Loss on debt extinguishment - - - Change in fair value of derivative liabilities (135,601 ) - (135,601 ) Deferred taxes - - - Depreciation and amortization 803,147 - 803,147 Share based compensation 148,476 - 148,476 Deferred rent (4,874 ) - (4,874 ) Changes in assets and liabilities Accounts receivable 1,067,854 - 1,067,854 Inventory 33,413 (337,050 ) (303,637 ) Prepaid expenses and other current assets 49,696 - 49,696 Accounts payable (1,130,583 ) - (1,130,583 ) Accrued expenses (465,416 ) - (465,416 ) Accrued commissions (72,546 ) - (72,546 ) Deferred rent - - - Net cash provided by operating activities 21,285 - 21,285 Cash flows from investing activities Purchases of property and equipment (22,103 ) - (22,103 ) Net cash used in investing activities (22,103 ) - (22,103 ) Cash flows from financing activities Proceeds from note payable - related party - - - Repayment of notes payable (1,057,811 ) - (1,057,811 ) Net cash used in financing activities (1,057,811 ) - (1,057,811 ) Net decrease in cash and cash equivalents (1,058,629 ) - (1,058,629 ) Cash and cash equivalents beginning of year 1,414,706 - 1,414,706 Cash and cash equivalents end of year $ 356,077 $ - $ 356,077

Note 4 - Inventory

Note 4 - Inventory	6 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Inventory Disclosure [Text Block]	4 . Inventory Inventory consists of the following: December 31, June 30, 2017 2017 Laboratory testing supplies $ 397,569 $ 347,750 Total inventory $ 397,569 $ 347,750 Purchased components of approximately $31,000 $207,000 six December 31, 2016 No six December 31, 2017.

Note 5 - Income Taxes

Note 5 - Income Taxes	6 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	5 . Income Taxes The Company 's effective tax rate for the three six December 31, 2017 179.5% 326.4%, $4,493,000, three six December 31, 2017, 35% On December 22, 2017, 2017 740, 740" three December 31, 2017, $4.5 At December 31, 2017, $7,357,000. $31,291,000 not

Note 6 - Related Party Notes Pa

Note 6 - Related Party Notes Payable	6 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Short-term Debt [Text Block]	6 . Related Party Notes Payable December 31, 2017 June 30, 2017 Note Interest rate Note Interest rate Payable per annum Payable per annum Secured Secured $ 1,056,875 5% interest paid annually $ 1,056,875 5% interest paid annually 641,294 5% interest paid annually 641,294 5% interest paid annually 255,417 5% interest paid annually 255,417 5% interest paid annually 591,613 5% interest paid annually 591,613 5% interest paid annually Total $ 2,545,199 Total $ 2,545,199 Secured At June 30, 2016, $950,000. $2.25 December 17, 2016. 422,222 85% 9% per annum with interest payable upon maturity or on any earlier redemption date. As described in greater detail below under the caption "Exchange Transaction", on March 20, 2017, $1,056,875. twelve 5% $2.03 At June 30, 2016, $320,000. April 15, 2016 10% first $4.86 September 1, 2016, December 1, 2016 5% $3.00 106,667 March 20, 2017, $200,000 $641,294. twelve 5% $2.03 Unsecured At June 30, 2016, $200,000, 20% per annum, payable in arrears, and was due upon the earlier of (i) August 26, 2016, 90 $5,000,000 September 1, 2016, December 1, 2016 90 $3.00 173,333 March 2017, $320,000 $641,294. twelve 5% 's assets and is convertible at the initial conversion price of $2.03 At June 30, 2016, $450,000 not 20% per annum, payable in arrears, and was due upon the earlier of (i) October 28, 2016, 30 90 $5,000,000 March 20, 2017, $591,613. twelve 5% $2.03 Effective as of January 31, 2017, $250,000 's Chief Executive Officer and Chairman of the Board. To evidence the loan, the Company issued Mr. Roshan a promissory note (the "Note") in the aggregate principal amount of $250,000. not 30 12% Exchange Transaction On March 20, 2017, $2,170,000 outstanding promissory notes (the "Original Notes"), which were due and payable, pursuant to which the Company agreed to issue the holders of such notes, in consideration of the cancellation of the Original Notes, new promissory notes in the aggregate principal amount of $2,545,199, $2.03 1,253,792 85% not $328,422. one $950,000 $2.25 $520,000 $3.00 $700,000 During the year ended June 30, 2017, the Company also agreed with the holder of all outstanding shares of Series B Convertible Preferred Stock (the "Series B Preferred Stock") to exchange all of its outstanding shares of Series B Preferred Stock for shares of a new series of convertible preferred stock designated as Series E Convertible Preferred Stock (the "Series E Preferred Stock"). Accordingly, on March 20, 2017, 25,000 $30.00 187,500 $4.00 4.99% may not 9.99% The New Notes bear interest at the rate of 5% redemption date. Beginning one 110% may 110% Loss on Extinguishment of Debt In accordance with ASC 470 50, Debt - Modifications and Extinguishments $258,037 2017. $328,422 $50,000 $120,385. No 2018.

Note 7 - Equity

Note 7 - Equity	6 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	7 . Equity Preferred Stock As of December 31, 2017, 25,000 187,500 $4.00 not $30.00 one 5% December 31, 2017, $29,000 . As of December 31, 2017, 605,000 619,154 $9.77139 may not $10.00 June 2016. 5% December 31, 2017, $787,000 The Company 's preferred stock takes precedence over Common Stock but ranks below debt in the event of liquidation. In addition, the Series D Convertible Preferred Stock ranks above the Series E Convertible Preferred Stock. Earnings per Share FASB ASC Topic 260, Earnings per Share three six December 31, 2017, Three Months Ended Six Months Ended December 31, December 31, 2017 2016 2017 2016 Basic earnings (loss) per share Net loss $ (2,983,867 ) $ (268,738 ) $ (4,110,390 ) $ (172,905 ) Preferred stock dividends (85,699 ) (100,624 ) (170,249 ) (201,248 ) Net loss available to common shareholders after preferred stock dividends $ (3,069,566 ) $ (369,362 ) $ (4,280,639 ) $ (374,153 ) Weighted average shares used in the computation of basic earning per share 7,249,370 6,015,053 7,249,370 5,893,655 Loss per share - basic $ (0.42 ) $ (0.06 ) $ (0.59 ) $ (0.06 ) Dilutive earnings (loss) per share Loss available to common shareholders $ (3,069,566 ) $ (369,362 ) $ (4,280,639 ) $ (374,153 ) Weighted average shares used in the computation of diluted earnings per share 7,249,370 6,015,053 7,249,370 5,893,655 Dilutive effect of options, warrants, convertible debt and convertible preferred stock - - - - Shares used in the computation of diluted earnings (loss) per share 7,249,370 6,015,053 7,249,370 5,893,655 Loss per share - diluted $ (0.42 ) $ (0.06 ) $ (0.59 ) $ (0.06 ) Anti-Dilutive Options Excluded 1,253,793 5,354,203 1,253,793 5,354,203 Common Stock Warrants A schedule of common stock warrant activity for the six December 31, 2017 Warrant Activity Number of Shares Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding June 30, 2017 4,150,535 $ 4.67 3.87 $ 42,582 Issued - Expired (25,000 ) $ 12.06 - Outstanding December 31, 2017 4,125,535 $ 4.62 2.89 $ - Exercisable, December 31, 2017 4,069,979 $ 4.18 2.79 $ -

Note 8 - Share-based Compensati

Note 8 - Share-based Compensation	6 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	8 . Share-Based Compensation Stock option activity under the Company 's stock option plans for employees and non-executive directors for the six December 31, 2017 Employee Option Activity Number of Options Weighted Average Exercise Price Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding June 30, 2017 226,902 9.04 6.34 $ - Granted 50,000 2.00 9.70 - Expired/Forfeited (11,556 ) 23.40 23.40 Outstanding December 31, 2017 265,346 7.08 7.04 $ - Exercisable December 31, 2017 143,917 11.50 4.94 $ - Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Non-Executive Option Activity Options Price Life (Years) Value Outstanding June 30, 2017 602,311 3.57 6.11 $ - Granted 45,555 1.59 9.74 - Expired/forfeited (35,901 ) 4.01 - - Outstanding and exercisable December 31, 2017 611,965 3.40 7.35 $ - No 's non-employee directors as of December 31, 2017 December 31, 2017. Restricted stock unit activity under the Company's restricted stock unit plans for employees and non-executive directors for the six December 31, 2017 Number of RSUs Weighted Average Grant Date Fair Value Outstanding June 30, 2017 411,429 $ 1.75 Granted 120,000 0.74 Expired/Forfeited - Outstanding December 31, 2017 531,429 $ 1.54

Note 9 - Fair Value Measurement

Note 9 - Fair Value Measurements and Other Financial Instruments	6 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Fair Value Disclosures [Text Block]	9 . Fair Value Measurements and Other Financial Instruments The carrying amounts of the Company 's financial assets and liabilities, such as cash, accounts receivable, inventory, prepaid expenses, and other current assets, accounts payable and accrued expenses approximate their fair values because of the short maturity of these instruments. I n connection with the issuance of a convertible promissory note as discussed in Note 6, The Company 's Level 3 2011 2015. three September 30, 2016 2017 The Company utilized the following assumptions in valuing the derivative conversion features: Exercise Price $2.03 - $2.07 Risk free interest rate 1.38% - 2.21% Expected volatility 100% - 160% Remaining Term (years) 0.22 - 5.57 Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis The fair value of AHC financial instruments, using the fair value hierarchy under U.S. GAAP detailed in "Fair Value Measurements" in Note 2, The Company uses Level 3 The following tables provide a summary of the changes in fair value, including net transfers in and/or out, of all financial assets/ (liabilities) measured at the fair value on a recurring basis using significant unobservable inputs during the six December 31, 2017. Convertible Warrants Notes Total Balance - June 30, 2017 $ 435,036 $ 116,004 $ 551,040 Change in fair value of derivative liabilities (254,553 ) (111,311 ) (365,864 ) Balance - December 31, 2017 $ 180,483 $ 4,693 $ 185,176 Fair Value Level 1 Level 2 Level 3 June 30, 2017 derivative liabilities $ 551,040 $ - $ - $ 551,040 December 31, 2017 derivative liabilities $ 185,176 $ - $ - $ 185,176 Derivative Instruments For the three six December 31, 2017 2016, $293,000 $366,000, $622,000 $136,000

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	6 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	10 . Commitments and Contingencies A complaint was filed by a former independent contractor in the State of Louisiana who was involved in the sales and marketing of the Company's products and services. The caption of the case is Medlogic, LLC and Malena F. Badon v. Peachstate Health Management, LLC., Pyarali Roy, and Universal Billing Systems, LLC not not Regarding the termination of the Company 's employment relationship with certain executives, including the former Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") of AHC, the Company has been reviewing its severance obligations to them and the vesting of other post-termination provisions. The Company believes that it has accrued all related severance costs as of December 31, 2017 The former CEO of AHC commenced arbitration proceedings against AHC before the American Arbitration Association ("AAA"). A demand for arbitration was filed with the AAA on or about June 22, 2016 'Connell Benjamin, requesting payment of severance compensation of $341,620 October 30, 2017, no The Company is a defendant in an action captioned Cogmedix, Inc. v. Authentidate Holding Corp. No. 1685CV01318B. September 6, 2016 $227,061, December 6, 2013. not On August 24, 2017, 38,321 Authentidate Holding Corp. and Peachstate Health Management, LLC d/b/a Aeon Clinical Laboratories v. Richard G. Hersperger, No. 2017 1686 December 2017, third $15,000 On May 3, 2017, 's compliance with applicable Federal Standards for Privacy of Individually Identifiable Health Information and/or Security Standards for the Protection of Electronic Protected Health Information. The OCR is the division of HHS charged with enforcing the Health Insurance Portability and Accountability Act of 1996, May 23, 2017 may, not The Company is the plaintiff in a case captioned Peachstate Health Management, LLC d/b/a Aeon Clinical Laboratories v. Radius Foundation, Inc. and William Bramlett, Ph.D. , June 13, 2017 October 10, 2017, $116,650. The Company is the plaintiff in a case captioned Peachstate Health Management, LLC d/b/a Aeon Clinical Laboratories v. Trimana, LLC d/b/a Via Medical Center April 29, 2016 October 11, 2017, November 10, 2017. No $104,442 The Company , along with its chief executive officer and certain unnamed persons, are defendants in a case captioned Carlotta Miraflor v. Peachstate Health Management, LLC d/b/a Aeon Global Health, et al. October 4, 2016 January 3, 2018 not The plaintiff was an independent contractor which provided marketing services to the Company pursuant to a services agreement. The complaint alleges harassment, retaliation, wrongful termination, assault, and other claims. The lawsuit was preceded by a Dismissal and Notice of Rights by the U.S. Equal Employment Opportunity Commission in July 2017 $75,000 The Company is also subject to claims and litigation arising in the ordinary course of business. Management considers that any liability from any reasonably foreseeable disposition of such claims and litigation, individually or in the aggregate, would not The Company has entered into various agreements by which it may may may third not Historically, the Company has not December 31, 2017, not

Note 11 - Related Party Transac

Note 11 - Related Party Transactions	6 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	11 . Related Party Transactions Except as disclosed herein, the Company has not 5% July 1, 2016. AEON leases its facilities from Centennial Properties of Georgia, LLC under a lease agreement commencing April 2014, January 20, 2016. 12 March 2026. $46,500 $60,000. first three six December 31, 2017 2016 $144,000 $288,000, $140,000 $279,000, The Company holds certain related part y notes payable with shareholders and affiliates of board members of the Company, as detailed in Note 6. $32,000 $64,000, $92,000 $203,000 three six December 31, 2017 2016, Effective as of January 31, 2017, $250,000 's Chief Executive Officer and Chairman of the Board. To evidence the loan, the Company issued Mr. Roshan a promissory note (the "Note") in the aggregate principal amount of $250,000. not 30 12% 6 AHC entered into a lease agreement with Hanif A. ("Sonny") Roshan (the "landlord") for a residential premises at 5455 30517 one January 1, 2017 December 31, 2017 $7,500 first 3% Rent expense was $22,500 $45,000 three six December 31, 2017.

Note 12 - Segment Information

Note 12 - Segment Information	6 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	1 2 . Segment Information The Compa ny is operated as two Selected financial information related to the Company's segments is presented below: Authentidate AEON Total Three Months ended December 31, 2017 Net revenues $ 253,180 $ 5,278,042 $ 5,531,222 Cost of revenues 64,978 823,564 888,541 Operating expenses 335,067 3,818,194 4,153,261 Operating loss (81,887 ) 1,459,848 1,377,961 Six Months ended December 31, 2017 Net revenues $ 500,850 $ 8,388,424 $ 8,889,274 Cost of revenues 120,106 1,897,012 2,017,117 Operating expenses 1,208,452 7,437,181 8,645,633 Operating loss (707,602 ) 951,243 243,641 Three Months Ended December 31, 2016 Net revenues $ 321,378 $ 4,565,435 $ 4,886,813 Cost of revenues 55,325 896,343 951,668 Operating expenses 1,320,216 4,319,576 5,639,792 Operating loss (160,596 ) (592,383 ) (752,979 ) Six Months ended December 31, 2016 Net revenues $ 680,157 $ 10,256,731 $ 10,936,888 Cost of revenues 356,783 1,839,055 2,195,838 Operating expenses 2,764,971 8,109,655 10,874,626 Operating income (loss) (143,361 ) 205,623 62,262 December 31, 2017 Total assets $ 7,474,180 $ 4,934,988.74 $ 12,409,168 June 30, 2017 Total assets $ 11,772,874 $ 4,958,804 $ 16,731,678

Note 13 - Subsequent Events

Note 13 - Subsequent Events	6 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	13. Subsequent Events On January 4, 2018, December 31, 2020; may 30 one $40,000 $25,000 February 1, 2018, $40,000 January 15, 2019 January 15, 2020. 280,000 RSUs 2011 Plan no On January 23, 2018 , the Company accepted a short-term loan in the aggregate principal amount of $500,000 $500,000. not April 23, 2018 5% may

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The Company 's condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and following the requirements of the Securities and Exchange Commission ("SEC") for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These interim financial statements have been prepared on the same basis as the Company's annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company's financial information. These interim results are not June 30, 2018 June 30, 2017, 2017 10 The balance sheet as of June 30, 2017 not l statements.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Esti mates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most sensitive accounting estimates affecting the financial statements are revenue recognition, the allowance for doubtful accounts, depreciation of long-lived assets, fair value of intangible assets and goodwill, amortization of intangible assets, income taxes and associated deferrals and valuation allowances, commitments and contingencies and measurement of derivative liabilities.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Accounts R eceivable, Net Accounts receivable represent customer obligations due under normal trade terms, net of allowance for doubtful accounts. The allowance for doubtful accounts reflects our best estimate of probable losses inherent in the accounts receivable balance. We determine the allowance based on known troubled accounts, historical experience and other currently available evidence. The allowance for doubtful accounts was approximately $887,000 $923,000 December 31, 2017 June 30, 2017,
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements The Company follows ASC 820 10, "Fair Value Measurements and Disclosures" 820 10 820 10 three three 820 10 Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, Level 3 Pricing inputs that are generally unobservable input and not The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lower priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one 3.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company provides laboratory testing services, web-based hosted so ftware services, telehealth products and post contract customer support services. In accordance with Financial Accounting Standards Board (" FASB") Accounting Standards Codification ("ASC") ASC- 605 "Revenue Recognition" third Revenue from laboratory testing services are recognized at the time test results are delivered, net of estimat ed contractual allowances. Third-party reimbursement revenue is estimated based on cash received over a 12 Revenue for hosted software services, telehealth products, and customer support services are recognized when persuasive evidence of an arrangement exists, delivery has occurred, the selling price is fixed and collectability is reasonably assured. Multiple-element arrangements are assessed to determine whether they can be separated into more than one one not
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk The Company maintains its cash in bank deposit acco unts which, at times, may December 31, 2017 June 30, 2017, $119,000 $871,000 not
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in tax laws or rates. The effect on deferred tax assets and liabilities of a change in tax rates will be recognized as income or expense in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. Management considers the likelihood of changes by taxing authorities in its filed income tax returns and recognizes a liability for or discloses potential changes that management believes are more likely than not not
Reclassification, Policy [Policy Text Block]	Reclassification Certain prior year amounts have been reclassified to conform to the current year presentation.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, 2014 09, "Revenue from Contracts with Customers" 606 2014 09" 2014 09, December 15, 2017, December 15, 2016. not July 1, 2018. In August 2014, No. 2014 15, "Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern". one one December 15, 2016 2014 15 10 In July 2015, 2015 11, "Inventory Topic 330 Simplifying the Measurement of Inventory" 2015 11 first 2015 11 December 15, 2016. no not In January 2016, issued ASU 2016 01, "Financial Instruments (Subtopic 825 10 Recognition and Measurements of Financial Assets and Financial Liabilities." 2016 01 may not first 2018. no not In February 2016, d ASU No. 2016 02, "Leases" 12 December 15, 2018, 2016 02 July 1, 2019. In March 2016, No. 2016 09, "Compensation-Stock Compensation (Topic 718 Payment Accounting" December 15, 2016, not not In August 2016, No. 2016 15, "Statement of Cash Flows (Topic 230 July 1, 2018 July 1, 2018. In November 2016, 2016 18, "Restricted Cash" first 2018 July 1, 2018. In May 2017, 2017 09, "Compensation-Stock Compensation (Topic 718 December 15, 2017. July 1, 2018. In July 2017, 2017 11, "Earnings Per Share (Topic 260 480 815 , no no 260 July 1, 2019. In December 2017, unting Bulletin No. 118, 740, Income Taxes December 22, 2017, No. 118 December 22, 2017. No. 118 10 December 31, 2017

Note 3 - Restatement and Corr20

Note 3 - Restatement and Correction of Error (Tables)	6 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	As Originally As Originally Reported As Restated Reported As Restated Three Months Three Months Six Months Six Months Ended Ended Ended Ended Dec 31, Dec 31, Dec 31, Dec 31, 2016 Adj 2016 2016 Adj 2016 Net revenues Fees for services $ 4,565,435 $ - $ 4,565,435 $ 10,256,731 $ - $ 10,256,731 Hosted software services 311,671 - 311,671 658,605 - 658,605 Telehealth services 9,707 - 9,707 21,552 - 21,552 Total net revenues 4,886,813 - 4,886,813 10,936,888 - 10,936,888 Operating expenses Cost of revenues 1,128,218 (176,550 ) 951,668 2,295,214 (337,050 ) 1,958,164 Write-down of inventory - - - 237,674 - 237,674 Selling, general and administrative 4,293,640 - 4,293,640 7,875,641 - 7,875,641 Depreciation and amortization 394,484 - 394,484 803,147 - 803,147 Total operating expenses 5,816,342 (176,550 ) 5,639,792 11,211,676 (337,050 ) 10,874,626 Operating income (loss) (929,529 ) 176,550 (752,979 ) (274,788 ) 337,050 62,262 Other (expense) income, net 529,645 - 529,645 (235,167 ) - (235,167 ) Income (loss) before provision for income taxes (399,884 ) 176,550 (223,334 ) (509,955 ) 337,050 (172,905 ) Income tax provision 45,404 - (45,404 ) - - - Net loss $ (445,288 ) $ 176,550 $ (268,738 ) $ (509,955 ) $ 337,050 $ (172,905 ) less: preferred dividends $ (100,624 ) $ - $ (100,624 ) $ (201,248 ) $ - $ (201,248 ) Net loss available to common shareholders $ (545,912 ) $ 176,550 $ (369,362 ) $ (711,203 ) $ 337,050 $ (374,153 ) Loss per share: Basic loss per common share $ (0.09 ) $ 0.03 $ (0.06 ) $ (0.12 ) $ 0.06 $ (0.06 ) Diluted loss per common share $ (0.09 ) $ 0.03 $ (0.06 ) $ (0.12 ) $ 0.06 $ (0.06 ) As Originally Reported As Restated Six Months Six Months Ended Ended Dec 31, Dec 31, 2016 Adj 2016 Cash Flows from Operating Activities Net Loss $ (509,955 ) $ 337,050 $ (172,905 ) Adjustments to reconcile net loss to cash provided by operating activities Write off of inventory 237,674 - 237,674 Loss on debt extinguishment - - - Change in fair value of derivative liabilities (135,601 ) - (135,601 ) Deferred taxes - - - Depreciation and amortization 803,147 - 803,147 Share based compensation 148,476 - 148,476 Deferred rent (4,874 ) - (4,874 ) Changes in assets and liabilities Accounts receivable 1,067,854 - 1,067,854 Inventory 33,413 (337,050 ) (303,637 ) Prepaid expenses and other current assets 49,696 - 49,696 Accounts payable (1,130,583 ) - (1,130,583 ) Accrued expenses (465,416 ) - (465,416 ) Accrued commissions (72,546 ) - (72,546 ) Deferred rent - - - Net cash provided by operating activities 21,285 - 21,285 Cash flows from investing activities Purchases of property and equipment (22,103 ) - (22,103 ) Net cash used in investing activities (22,103 ) - (22,103 ) Cash flows from financing activities Proceeds from note payable - related party - - - Repayment of notes payable (1,057,811 ) - (1,057,811 ) Net cash used in financing activities (1,057,811 ) - (1,057,811 ) Net decrease in cash and cash equivalents (1,058,629 ) - (1,058,629 ) Cash and cash equivalents beginning of year 1,414,706 - 1,414,706 Cash and cash equivalents end of year $ 356,077 $ - $ 356,077

Note 4 - Inventory (Tables)

Note 4 - Inventory (Tables)	6 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, June 30, 2017 2017 Laboratory testing supplies $ 397,569 $ 347,750 Total inventory $ 397,569 $ 347,750

Note 6 - Related Party Notes 22

Note 6 - Related Party Notes Payable (Tables)	6 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Debt [Table Text Block]	December 31, 2017 June 30, 2017 Note Interest rate Note Interest rate Payable per annum Payable per annum Secured Secured $ 1,056,875 5% interest paid annually $ 1,056,875 5% interest paid annually 641,294 5% interest paid annually 641,294 5% interest paid annually 255,417 5% interest paid annually 255,417 5% interest paid annually 591,613 5% interest paid annually 591,613 5% interest paid annually Total $ 2,545,199 Total $ 2,545,199

Note 7 - Equity (Tables)

Note 7 - Equity (Tables)	6 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Six Months Ended December 31, December 31, 2017 2016 2017 2016 Basic earnings (loss) per share Net loss $ (2,983,867 ) $ (268,738 ) $ (4,110,390 ) $ (172,905 ) Preferred stock dividends (85,699 ) (100,624 ) (170,249 ) (201,248 ) Net loss available to common shareholders after preferred stock dividends $ (3,069,566 ) $ (369,362 ) $ (4,280,639 ) $ (374,153 ) Weighted average shares used in the computation of basic earning per share 7,249,370 6,015,053 7,249,370 5,893,655 Loss per share - basic $ (0.42 ) $ (0.06 ) $ (0.59 ) $ (0.06 ) Dilutive earnings (loss) per share Loss available to common shareholders $ (3,069,566 ) $ (369,362 ) $ (4,280,639 ) $ (374,153 ) Weighted average shares used in the computation of diluted earnings per share 7,249,370 6,015,053 7,249,370 5,893,655 Dilutive effect of options, warrants, convertible debt and convertible preferred stock - - - - Shares used in the computation of diluted earnings (loss) per share 7,249,370 6,015,053 7,249,370 5,893,655 Loss per share - diluted $ (0.42 ) $ (0.06 ) $ (0.59 ) $ (0.06 ) Anti-Dilutive Options Excluded 1,253,793 5,354,203 1,253,793 5,354,203
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrant Activity Number of Shares Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding June 30, 2017 4,150,535 $ 4.67 3.87 $ 42,582 Issued - Expired (25,000 ) $ 12.06 - Outstanding December 31, 2017 4,125,535 $ 4.62 2.89 $ - Exercisable, December 31, 2017 4,069,979 $ 4.18 2.79 $ -

Note 8 - Share-based Compensa24

Note 8 - Share-based Compensation (Tables)	6 Months Ended
	Dec. 31, 2017
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Employee Option Activity Number of Options Weighted Average Exercise Price Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding June 30, 2017 226,902 9.04 6.34 $ - Granted 50,000 2.00 9.70 - Expired/Forfeited (11,556 ) 23.40 23.40 Outstanding December 31, 2017 265,346 7.08 7.04 $ - Exercisable December 31, 2017 143,917 11.50 4.94 $ - Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Non-Executive Option Activity Options Price Life (Years) Value Outstanding June 30, 2017 602,311 3.57 6.11 $ - Granted 45,555 1.59 9.74 - Expired/forfeited (35,901 ) 4.01 - - Outstanding and exercisable December 31, 2017 611,965 3.40 7.35 $ -
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	Number of RSUs Weighted Average Grant Date Fair Value Outstanding June 30, 2017 411,429 $ 1.75 Granted 120,000 0.74 Expired/Forfeited - Outstanding December 31, 2017 531,429 $ 1.54

Note 9 - Fair Value Measureme25

Note 9 - Fair Value Measurements and Other Financial Instruments (Tables)	6 Months Ended
	Dec. 31, 2017
Notes Tables
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	Exercise Price $2.03 - $2.07 Risk free interest rate 1.38% - 2.21% Expected volatility 100% - 160% Remaining Term (years) 0.22 - 5.57
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Convertible Warrants Notes Total Balance - June 30, 2017 $ 435,036 $ 116,004 $ 551,040 Change in fair value of derivative liabilities (254,553 ) (111,311 ) (365,864 ) Balance - December 31, 2017 $ 180,483 $ 4,693 $ 185,176
Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]	Fair Value Level 1 Level 2 Level 3 June 30, 2017 derivative liabilities $ 551,040 $ - $ - $ 551,040 December 31, 2017 derivative liabilities $ 185,176 $ - $ - $ 185,176

Note 12 - Segment Information (

Note 12 - Segment Information (Tables)	6 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Authentidate AEON Total Three Months ended December 31, 2017 Net revenues $ 253,180 $ 5,278,042 $ 5,531,222 Cost of revenues 64,978 823,564 888,541 Operating expenses 335,067 3,818,194 4,153,261 Operating loss (81,887 ) 1,459,848 1,377,961 Six Months ended December 31, 2017 Net revenues $ 500,850 $ 8,388,424 $ 8,889,274 Cost of revenues 120,106 1,897,012 2,017,117 Operating expenses 1,208,452 7,437,181 8,645,633 Operating loss (707,602 ) 951,243 243,641 Three Months Ended December 31, 2016 Net revenues $ 321,378 $ 4,565,435 $ 4,886,813 Cost of revenues 55,325 896,343 951,668 Operating expenses 1,320,216 4,319,576 5,639,792 Operating loss (160,596 ) (592,383 ) (752,979 ) Six Months ended December 31, 2016 Net revenues $ 680,157 $ 10,256,731 $ 10,936,888 Cost of revenues 356,783 1,839,055 2,195,838 Operating expenses 2,764,971 8,109,655 10,874,626 Operating income (loss) (143,361 ) 205,623 62,262 December 31, 2017 Total assets $ 7,474,180 $ 4,934,988.74 $ 12,409,168 June 30, 2017 Total assets $ 11,772,874 $ 4,958,804 $ 16,731,678

Note 1 - Description of Busin27

Note 1 - Description of Business, Reverse Merger and Liquidity (Details Textual) - USD ($)	Jan. 26, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016
Short-term Debt		$ 2,545,199	$ 2,545,199
Cash and Cash Equivalents, at Carrying Value		357,165	1,121,763	$ 356,077	$ 1,414,706
Working Capital (Deficit)		5,074,000
Estimated Monthly Operational Requirement		1,300,000
Secured Convertible Note Payable [Member]
Short-term Debt		$ 2,545,199	$ 2,545,199
Subsequent Event [Member]
Cash and Cash Equivalents, at Carrying Value	$ 1,057,000
Subsequent Event [Member] | Subordinated Secured Note Payable [Member] | Former Chief Financial Officer [Member] | Accrued Expenses [Member]
Due to Related Parties	210,000
Subsequent Event [Member] | Secured Convertible Note Payable [Member]
Short-term Debt	$ 2,545,199

Note 2 - Summary of Significa28

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Dec. 31, 2017	Jun. 30, 2017
Allowance for Doubtful Accounts Receivable, Current	$ 887,000	$ 923,000
Cash, Uninsured Amount	$ 119,000	$ 871,000

Note 3 - Restatement and Corr29

Note 3 - Restatement and Correction of Error - Restated Statements of Income and Cash Flows (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Jun. 30, 2017
Net revenues
Fees for services	$ 5,278,042	$ 4,565,435	$ 8,388,424	$ 10,256,731
Hosted software services	248,530	311,671	491,550	658,605
Telehealth services	4,650	9,707	9,300	21,552
Net revenues	5,531,222	4,886,813	8,889,274	10,936,888
Operating expenses
Cost of revenues	888,541	951,668	2,017,117	2,195,838
Inventory Write-down			0	237,674
Selling, general and administrative	3,042,771	4,204,114	6,153,936	7,727,165
Depreciation and amortization	200,837	394,484	423,421	803,147
Operating expenses	4,153,261	5,639,792	8,645,633	10,874,626
Operating income (loss)	1,377,961	(752,979)	243,641	62,262
Other (expense) income, net	131,411	529,645	139,208	(235,167)
Income (loss) before provision for income taxes	1,509,372	(223,334)	382,849	(172,905)
Income tax provision	(4,493,239)	(45,404)	(4,493,239)
Net loss	(2,983,867)	(268,738)	(4,110,390)	(172,905)
Less: preferred dividends	(85,699)	(100,624)	(170,249)	(201,248)
Net loss available to common shareholders after preferred stock dividends	$ (3,069,566)	$ (369,362)	$ (4,280,639)	$ (374,153)
Loss per share:
Basic loss per common share (in dollars per share)	$ (0.42)	$ (0.06)	$ (0.59)	$ (0.06)
Diluted loss per common share (in dollars per share)	$ (0.42)	$ (0.06)	$ (0.59)	$ (0.06)
Cash flows from operating activities
Net loss	$ (2,983,867)	$ (268,738)	$ (4,110,390)	$ (172,905)
Adjustments to reconcile net income (loss) to net cash used by operating activities
Inventory Write-down			0	237,674
Loss on debt extinguishment
Change in fair value of derivative liabilities			(365,864)	(135,601)
Deferred taxes
Depreciation and amortization	200,837	394,484	423,421	803,147
Share based compensation	21,111	89,526	51,159	148,476
Deferred rent				(4,874)
Changes in assets and liabilities
Accounts receivable			(1,446,948)	1,067,894
Inventory			(49,819)	(303,637)
Prepaid expenses and other current assets			19,982	49,696
Accounts payable			(650,497)	(1,130,623)
Accrued expenses			325,285	(465,416)
Accrued commissions			427,797	(72,546)
Deferred rent				4,874
Net cash provided by operating activities			(764,598)	21,285
Cash flows from investing activities
Purchases of property and equipment				(22,103)
Net cash used in investing activities				(22,103)
Cash flows from financing activities
Proceeds from note payable - related party
Repayment of notes payable				(1,057,811)
Net cash used in financing activities				(1,057,811)
Net decrease in cash and cash equivalents			(764,598)	(1,058,629)
Cash beginning of period			1,121,763	1,414,706	$ 1,414,706
Cash end of period	$ 357,165	356,077	$ 357,165	356,077	1,121,763
Scenario, Previously Reported [Member]
Net revenues
Fees for services		4,565,435		10,256,731
Hosted software services		311,671		658,605
Telehealth services		9,707		21,552
Net revenues		4,886,813		10,936,888
Operating expenses
Cost of revenues		1,128,218		2,295,214
Inventory Write-down				237,674
Selling, general and administrative		4,293,640		7,875,641
Depreciation and amortization		394,484		803,147
Operating expenses		5,816,342		11,211,676
Operating income (loss)		(929,529)		(274,788)
Other (expense) income, net		529,645		(235,167)
Income (loss) before provision for income taxes		(399,884)		(509,955)
Income tax provision		45,404
Net loss		(445,288)		(509,955)
Less: preferred dividends		(100,624)		(201,248)
Net loss available to common shareholders after preferred stock dividends		$ (545,912)		$ (711,203)
Loss per share:
Basic loss per common share (in dollars per share)		$ (0.09)		$ (0.12)
Diluted loss per common share (in dollars per share)		$ (0.09)		$ (0.12)
Cash flows from operating activities
Net loss		$ (445,288)		$ (509,955)
Adjustments to reconcile net income (loss) to net cash used by operating activities
Inventory Write-down				237,674
Loss on debt extinguishment
Change in fair value of derivative liabilities				(135,601)
Deferred taxes
Depreciation and amortization		394,484		803,147
Share based compensation				148,476
Deferred rent				(4,874)
Changes in assets and liabilities
Accounts receivable				1,067,854
Inventory				33,413
Prepaid expenses and other current assets				49,696
Accounts payable				(1,130,583)
Accrued expenses				(465,416)
Accrued commissions				(72,546)
Deferred rent
Net cash provided by operating activities				21,285
Cash flows from investing activities
Purchases of property and equipment				(22,103)
Net cash used in investing activities				(22,103)
Cash flows from financing activities
Proceeds from note payable - related party
Repayment of notes payable				(1,057,811)
Net cash used in financing activities				(1,057,811)
Net decrease in cash and cash equivalents				(1,058,629)
Cash beginning of period				1,414,706	1,414,706
Cash end of period		356,077		356,077
Restatement Adjustment [Member]
Net revenues
Fees for services
Hosted software services
Telehealth services
Net revenues
Operating expenses
Cost of revenues		(176,550)		(337,050)
Inventory Write-down
Selling, general and administrative
Depreciation and amortization
Operating expenses		(176,550)		(337,050)
Operating income (loss)		176,550		337,050
Other (expense) income, net
Income (loss) before provision for income taxes		176,550		337,050
Income tax provision
Net loss		176,550		337,050
Less: preferred dividends
Net loss available to common shareholders after preferred stock dividends		$ 176,550		$ 337,050
Loss per share:
Basic loss per common share (in dollars per share)		$ 0.03		$ 0.06
Diluted loss per common share (in dollars per share)		$ 0.03		$ 0.06
Cash flows from operating activities
Net loss		$ 176,550		$ 337,050
Adjustments to reconcile net income (loss) to net cash used by operating activities
Inventory Write-down
Loss on debt extinguishment
Change in fair value of derivative liabilities
Deferred taxes
Depreciation and amortization
Share based compensation
Deferred rent
Changes in assets and liabilities
Accounts receivable
Inventory				(337,050)
Prepaid expenses and other current assets
Accounts payable
Accrued expenses
Accrued commissions
Deferred rent
Net cash provided by operating activities
Cash flows from investing activities
Purchases of property and equipment
Net cash used in investing activities
Cash flows from financing activities
Proceeds from note payable - related party
Repayment of notes payable
Net cash used in financing activities
Net decrease in cash and cash equivalents
Cash beginning of period
Cash end of period

Note 4 - Inventory (Details Tex

Note 4 - Inventory (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Inventory Write-down			$ 0	$ 237,674
Purchased Components [Member]
Inventory Write-down				31,000
Finished Goods [Member]
Inventory Write-down				$ 207,000

Note 4 - Inventory - Inventory

Note 4 - Inventory - Inventory (Details) - USD ($)	Dec. 31, 2017	Jun. 30, 2017
Laboratory testing supplies	$ 397,569	$ 347,750
Total inventory	$ 397,569	$ 347,750

Note 5 - Income Taxes (Details

Note 5 - Income Taxes (Details Textual) - USD ($)	3 Months Ended	6 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Effective Income Tax Rate Reconciliation, Percent	179.50%	326.40%
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability	$ 4,493,000	$ 4,490,581
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent		35.00%
Deferred Tax Assets, Net	7,357,000	$ 7,357,000
Deferred Tax Assets, Valuation Allowance	$ 31,291,000	$ 31,291,000

Note 6 - Related Party Notes 33

Note 6 - Related Party Notes Payable (Details Textual)	Mar. 20, 2017USD ($)$ / shares	Jan. 31, 2017USD ($)	Sep. 01, 2016$ / shares	Jun. 30, 2017USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)	Jun. 30, 2017USD ($)$ / sharesshares	Jun. 30, 2016USD ($)$ / shares	Mar. 19, 2017USD ($)
Preferred Stock, Par or Stated Value Per Share | $ / shares				$ 0.10	$ 0.10		$ 0.10
Gain (Loss) on Extinguishment of Debt
Series E Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Exchange of Convertible Securities | shares				25,000
Preferred Stock, Par or Stated Value Per Share | $ / shares				$ 30	$ 30		$ 30
Convertible Preferred Stock, Aggregate Shares Issued upon Conversion | shares				187,500	187,500		187,500
Convertible Preferred Stock, Conversion Price | $ / shares				$ 4	$ 4		$ 4
Convertible Preferred Stock, Beneficial Ownership Limitation for Conversion Rights without Issuer Consent				4.99%			4.99%
Convertible Preferred Stock, Beneficial Ownership Limitation for Conversion Rights with Issuer Consent				9.99%			9.99%
Stock Issued During Period, Excess Value, Exchange of Convertible Securities				$ 50,000
Series B Preferred Stock [Member]
Preferred Stock, Preferred Dividends in Arrears Waived During Period				$ 120,385
Original Notes [Member]
Debt Instrument, Face Amount	$ 2,170,000
Gain (Loss) on Extinguishment of Debt					$ 0		$ (258,037)
New Notes [Member]
Debt Instrument, Face Amount	$ 2,545,199
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 2.03
Debt Instrument, Convertible, Number of Equity Instruments	1,253,792
Debt Instrument, Percentage of Conversion Price to Price per Share if Lower than Original Conversion Price	85.00%
Debt Instrument, Interest Rate, Stated Percentage					5.00%
Debt Instrument, Term	1 year
Embedded Derivative, Fair Value of Embedded Derivative Liability	$ 328,422
Debt Instrument, Period Following National Securities Exchange Listing of Common Stock to Commence Redemption Right by Debtor					30 days
Debt Instrument, Redemption Price, Percentage					110.00%
Debt Instrument, Event of Default, Outstanding Principal and Interest Payable at Lenders' Option, Percent					110.00%
Unsecured Promissory Note [Member] | Original Notes [Member] | Optimum Ventures, LLC and Hanif A. Roshan [Member]
Debt Instrument, Face Amount	700,000
Secured Convertible Note Payable [Member] | Lender One [Member]
Debt Instrument, Face Amount	$ 1,056,875							$ 950,000
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 2.03							$ 2.25
Debt Instrument, Convertible, Number of Equity Instruments								422,222
Debt Instrument, Percentage of Conversion Price to Price per Share if Lower than Original Conversion Price								85.00%
Debt Instrument, Interest Rate, Stated Percentage	5.00%							9.00%
Debt Instrument, Term	1 year
Secured Convertible Note Payable [Member] | Lender One [Member] | Original Notes [Member]
Debt Instrument, Face Amount	$ 950,000
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 2.25
Secured Convertible Note Payable [Member] | J. David Luce [Member]
Debt Instrument, Face Amount	$ 641,294							$ 320,000	$ 320,000
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 2.03		$ 3					$ 4.86
Debt Instrument, Convertible, Number of Equity Instruments			106,667
Debt Instrument, Interest Rate, Stated Percentage	5.00%		5.00%					10.00%
Debt Instrument, Term	1 year
Secured Convertible Note Payable [Member] | Optimum Ventures, LLC [Member]
Debt Instrument, Face Amount	$ 591,613
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 2.03
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Debt Instrument, Term	1 year
Unsecured Promissory Note [Member] | J. David Luce [Member]
Debt Instrument, Face Amount	$ 200,000							$ 200,000
Debt Instrument, Convertible, Conversion Price | $ / shares			$ 3
Debt Instrument, Convertible, Number of Equity Instruments			173,333
Debt Instrument, Interest Rate, Stated Percentage								20.00%
Debt Instrument, Period Following Issuance in which Sale of Equity or Debt Securities Above Threshold Would Trigger Maturity								90 days
Debt Instrument, Sale of Equity or Debt Securities, Threshold that Would Trigger Maturity								$ 5,000,000
Debt Instrument, Extension Period at Lender Option			90 days
Unsecured Promissory Note [Member] | Optimum Ventures, LLC [Member]
Debt Instrument, Face Amount								$ 450,000
Debt Instrument, Interest Rate, Stated Percentage								20.00%
Debt Instrument, Period Following Issuance in which Sale of Equity or Debt Securities Above Threshold Would Trigger Maturity								90 days
Debt Instrument, Sale of Equity or Debt Securities, Threshold that Would Trigger Maturity								$ 5,000,000
Debt Instrument, Sale of Equity or Debt Securities Above Threshold, Period to Maturity								30 days
Unsecured Promissory Note [Member] | Hanif A. Roshan [Member]
Debt Instrument, Face Amount		$ 250,000
Debt Instrument, Interest Rate, Stated Percentage		12.00%
Debt Instrument, Term		30 days
Convertible Notes Payable [Member] | J. David Luce [Member] | Original Notes [Member]
Debt Instrument, Face Amount	$ 520,000
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 3

Note 6 - Related Party Notes 34

Note 6 - Related Party Notes Payable - Related Party Notes Payable (Details) - USD ($)	Dec. 31, 2017	Jun. 30, 2017
Related party notes payable	$ 2,545,199	$ 2,545,199
Secured Convertible Note Payable [Member]
Related party notes payable	2,545,199	2,545,199
Secured Convertible Note Payable [Member] | Lender One [Member]
Related party notes payable	$ 1,056,875	$ 1,056,875
Debt instrument, stated percentage	5.00%	5.00%
Secured Convertible Note Payable [Member] | J. David Luce [Member]
Related party notes payable	$ 641,294	$ 641,294
Debt instrument, stated percentage	5.00%	5.00%
Secured Convertible Note Payable [Member] | Hanif A. Roshan [Member]
Related party notes payable	$ 255,417	$ 255,417
Debt instrument, stated percentage	5.00%	5.00%
Secured Convertible Note Payable [Member] | Optimum Ventures, LLC [Member]
Related party notes payable	$ 591,613	$ 591,613
Debt instrument, stated percentage	5.00%	5.00%

Note 7 - Equity (Details Textua

Note 7 - Equity (Details Textual) - USD ($)	6 Months Ended
	Dec. 31, 2017	Jun. 30, 2017
Preferred Stock, Par or Stated Value Per Share	$ 0.10	$ 0.10
Series E Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding	25,000	25,000
Convertible Preferred Stock, Aggregate Shares Issued upon Conversion	187,500	187,500
Convertible Preferred Stock, Conversion Price	$ 4	$ 4
Preferred Stock, Par or Stated Value Per Share	$ 30	$ 30
Preferred Stock, Period Following Issuance Date to Initiate Redemption	1 year
Preferred Stock, Dividend Rate, Percentage	5.00%
Dividends Payable	$ 29,000
Series D Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding	605,000	605,000
Convertible Preferred Stock, Aggregate Shares Issued upon Conversion	619,154
Convertible Preferred Stock, Conversion Price	$ 9.77139
Preferred Stock, Dividend Rate, Percentage	5.00%
Dividends Payable	$ 787,000
Preferred Stock, Redemption Price Per Share	$ 10

Note 7 - Equity - Earnings Per

Note 7 - Equity - Earnings Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Basic earnings (loss) per share
Net loss	$ (2,983,867)	$ (268,738)	$ (4,110,390)	$ (172,905)
Preferred stock dividends	(85,699)	(100,624)	(170,249)	(201,248)
Net loss available to common shareholders after preferred stock dividends	$ (3,069,566)	$ (369,362)	$ (4,280,639)	$ (374,153)
Weighted average shares used in the computation of basic earning per share (in shares)	7,249,370	6,015,053	7,249,370	5,893,655
Loss per share - basic (in dollars per share)	$ (0.42)	$ (0.06)	$ (0.59)	$ (0.06)
Dilutive earnings (loss) per share
Loss available to common shareholders	$ (3,069,566)	$ (369,362)	$ (4,280,639)	$ (374,153)
Weighted average shares used in the computation of diluted earnings per share (in shares)	7,249,370	6,015,053	7,249,370	5,893,655
Dilutive effect of options, warrants, convertible debt and convertible preferred stock (in shares)
Shares used in the computation of diluted earnings (loss) per share (in shares)	7,249,370	6,015,053	7,249,370	5,893,655
Loss per share - diluted (in dollars per share)	$ (0.42)	$ (0.06)	$ (0.59)	$ (0.06)
Employee Stock Option [Member]
Dilutive earnings (loss) per share
Anti-Dilutive Options Excluded (in shares)	1,253,793	5,354,203	1,253,793	5,354,203

Note 7 - Equity - Warrant Activ

Note 7 - Equity - Warrant Activity (Details) - Warrant [Member] - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Jun. 30, 2017
Warrants outstanding (in shares)	4,150,535
Warrants outstanding, weighted average exercise price per share (in dollars per share)	$ 4.62	$ 4.67
Warrants outstanding, weighted average remaining contractual life (Year)	2 years 324 days	3 years 317 days
Warrants outstanding, aggregate intrinsic value		$ 42,582
Warrants issued (in shares)
Warrants expired (in shares)	(25,000)
Warrants expired, weighted average exercise price per share (in dollars per share)	$ 12.06
Warrants outstanding (in shares)	4,125,535	4,150,535
Warrants exercisable	$ 4,069,979
Warrants exercisable, weighted average exercise price per share (in dollars per share)	$ 4.18
Warrants exercisable, weighted average remaining contractual life (Year)	2 years 288 days
Warrants exercisable, aggregate intrinsic value

Note 8 - Share-based Compensa38

Note 8 - Share-based Compensation (Details Textual) shares in Thousands	6 Months Ended
	Dec. 31, 2017shares
Non-employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0

Note 8 - Share-based Compensa39

Note 8 - Share-based Compensation - Stock Option Activity (Details) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2017
Employees [Member]
Outstanding, beginning of period (in shares)	226,902
Outstanding, weighted average exercise price (in dollars per share)	$ 9.04
Outstanding, average remaining contractual life (Year)	7 years 14 days	6 years 124 days
Outstanding, aggregate intrinsic value
Number of options granted (in shares)	50,000
Granted, weighted average exercise price (in dollars per share)	$ 2
Granted, average remaining contractual life (Year)	9 years 255 days
Granted, aggregate intrinsic value
Number of options expired/forfeited (in shares)	(11,556)
Expired/forfeited, weighted average exercise price (in dollars per share)	$ 23.40
Expired/forfeited, average remaining contractual life (Year)	23 years 146 days
Expired/forfeited, aggregate intrinsic value
Outstanding, end of period (in shares)	265,346	226,902
Outstanding, weighted average exercise price (in dollars per share)	$ 7.08	$ 9.04
Outstanding, aggregate intrinsic value
Exercisable (in shares)			143,917
Exercisable, weighted average exercise price (in dollars per share)			$ 11.50
Exercisable, average remaining contractual life (Year)	4 years 343 days
Exercisable, aggregate intrinsic value
Non-Executives [Member]
Outstanding, beginning of period (in shares)	602,311
Outstanding, weighted average exercise price (in dollars per share)	$ 3.57
Outstanding, average remaining contractual life (Year)	7 years 127 days	6 years 40 days
Outstanding, aggregate intrinsic value
Number of options granted (in shares)	45,555
Granted, weighted average exercise price (in dollars per share)	$ 1.59
Granted, average remaining contractual life (Year)	9 years 270 days
Granted, aggregate intrinsic value
Number of options expired/forfeited (in shares)	(35,901)
Expired/forfeited, weighted average exercise price (in dollars per share)	$ 4.01
Expired/forfeited, aggregate intrinsic value
Outstanding, end of period (in shares)	611,965	602,311
Outstanding, weighted average exercise price (in dollars per share)	$ 3.40	$ 3.57
Outstanding, aggregate intrinsic value
Exercisable, aggregate intrinsic value

Note 8 - Share-based Compensa40

Note 8 - Share-based Compensation - Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Dec. 31, 2017$ / sharesshares
Number of RSUs outstanding (in shares) | shares	411,429
RSUs outstanding, weighted average grant date fair value (in dollars per share) | $ / shares	$ 1.75
Number of RSUs granted (in shares) | shares	120,000
RSUs granted, weighted average grant date fair value (in dollars per share) | $ / shares	$ 0.74
Number of RSUs expired/forfeited (in shares) | shares
RSUs expired/forfeited, weighted average grant date fair value (in dollars per share) | $ / shares
Number of RSUs outstanding (in shares) | shares	531,429
RSUs outstanding, weighted average grant date fair value (in dollars per share) | $ / shares	$ 1.54

Note 9 - Fair Value Measureme41

Note 9 - Fair Value Measurements and Other Financial Instruments (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Gain (Loss) on Derivative Instruments, Net, Pretax	$ 292,573	$ 621,820	$ 365,864	$ 135,601

Note 9 - Fair Value Measureme42

Note 9 - Fair Value Measurements and Other Financial Instruments - Valuation Techniques (Details)	6 Months Ended
	Dec. 31, 2017$ / shares
Exercise Price (in dollars per share)
Expected volatility
Minimum [Member]
Exercise Price (in dollars per share)	$ 2.03
Risk free interest rate	1.38%
Expected volatility	100.00%
Remaining Term (years) (Year)	80 days
Maximum [Member]
Exercise Price (in dollars per share)	$ 2.07
Risk free interest rate	2.21%
Expected volatility	160.00%
Remaining Term (years) (Year)	5 years 208 days

Note 9 - Fair Value Measureme43

Note 9 - Fair Value Measurements and Other Financial Instruments - Summary in Changes in Fair Value (Details)	6 Months Ended
	Dec. 31, 2017USD ($)
Balance, beginning of period	$ 551,040
Change in fair value of derivative liabilities	(365,864)
Balance, end of period	185,176
Warrant [Member]
Balance, beginning of period	435,036
Change in fair value of derivative liabilities	(254,553)
Balance, end of period	180,483
Convertible Notes [Member]
Balance, beginning of period	116,004
Change in fair value of derivative liabilities	(111,311)
Balance, end of period	$ 4,693

Note 9 - Fair Value Measureme44

Note 9 - Fair Value Measurements and Other Financial Instruments - Derivative Liabilities (Details) - USD ($)	Dec. 31, 2017	Jun. 30, 2017
Derivative liabilities	$ 185,176	$ 551,040
Fair Value, Inputs, Level 1 [Member]
Derivative liabilities
Fair Value, Inputs, Level 2 [Member]
Derivative liabilities
Fair Value, Inputs, Level 3 [Member]
Derivative liabilities	$ 185,176	$ 551,040

Note 10 - Commitments and Con45

Note 10 - Commitments and Contingencies (Details Textual) - USD ($)	Oct. 11, 2017	Oct. 10, 2017	Aug. 24, 2017	Oct. 04, 2016	Sep. 06, 2016	Jun. 22, 2016	Dec. 31, 2017
Severance Compensation Arbitration Filed by Former CEO [Member]
Loss Contingency, Damages Sought, Value						$ 341,620
Cogmedix, Inc. v. Authentidate Holding Corp [Member]
Loss Contingency, Damages Sought, Value					$ 227,061
Authentidate Holding Corp. and Peachstate Health Management, LLC d/b/a Aeon Clinical Laboratories v. Richard G. Hersperger [Member]
Litigation Case, Number of Shares Sought to Recover by Plaintiff			38,321
Litigation Settlement, Amount Awarded to Other Party							$ 15,000
Peachstate Health Management, LLC d/b/a Aeon Clinical Laboratories v. Radius Foundation, Inc. and William Bramlett, Ph.D. [Member]
Loss Contingency, Damages Sought, Value		$ 116,650
Peachstate Health Management, LLC d/b/a Aeon Clinical Laboratories v. Trimana, LLC d/b/a Via Medical Center [Member]
Loss Contingency, Damages Sought, Value	$ 104,442
Carlotta Miraflor v. Peachstate Health Management, LLC d/b/a Aeon Global Health, et al. [Member]
Loss Contingency, Damages Sought, Value				$ 75,000

Note 11 - Related Party Trans46

Note 11 - Related Party Transactions (Details Textual) - USD ($)	Jan. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017
Interest Expense, Related Party		$ 32,000	$ 92,000	$ 64,000	$ 203,000
Hanif A. Roshan [Member] | Unsecured Promissory Note [Member]
Debt Instrument, Face Amount	$ 250,000
Debt Instrument, Term	30 days
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Facilities Leased [Member] | Centennial Properties of Georgia, LLC [Member]
Lessee, Operating Lease, Term of Contract				12 years
Operating Leases, Rent Expense, Net		144,000	$ 140,000	$ 288,000	$ 279,000
Facilities Leased [Member] | Centennial Properties of Georgia, LLC [Member] | Minimum [Member]
Operating Leases, Monthly Rent Expense				46,500
Facilities Leased [Member] | Centennial Properties of Georgia, LLC [Member] | Maximum [Member]
Operating Leases, Monthly Rent Expense				60,000
Residential Premises Leased [Member] | Hanif A. Roshan [Member]
Lessee, Operating Lease, Term of Contract						1 year
Operating Leases, Monthly Rent Expense						$ 7,500
Operating Leases, Rent Expense, Net		$ 22,500		$ 45,000
Operating Leases, Increase in Rent Expense Upon Each Renewal						3.00%

Note 12 - Segment Information47

Note 12 - Segment Information (Details Textual)	6 Months Ended
	Dec. 31, 2017
Number of Operating Segments	2

Note 12 - Segment Information -

Note 12 - Segment Information - Selected Financial Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Jun. 30, 2017
Net revenues	$ 5,531,222	$ 4,886,813	$ 8,889,274	$ 10,936,888
Cost of revenues	888,541	951,668	2,017,117	2,195,838
Operating expenses	4,153,261	5,639,792	8,645,633	10,874,626
Operating income (loss)	1,377,961	(752,979)	243,641	62,262
Total assets	12,409,168		12,409,168		$ 16,731,678
Web-based Software [Member]
Net revenues	253,180	321,378	500,850	680,157
Cost of revenues	64,978	55,325	120,106	356,783
Operating expenses	335,067	1,320,216	1,208,452	2,764,971
Operating income (loss)	(81,887)	(160,596)	(707,602)	(143,361)
Total assets	7,474,180		7,474,180		11,772,874
Laboratory Testing Services [Member]
Net revenues	5,278,042	4,565,435	8,388,424	10,256,731
Cost of revenues	823,564	896,343	1,897,012	1,839,055
Operating expenses	3,818,194	4,319,576	7,437,181	8,109,655
Operating income (loss)	1,459,848	$ (592,383)	951,243	$ 205,623
Total assets	$ 4,934,988.74		$ 4,934,988.74		$ 4,958,804

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - USD ($)	Feb. 01, 2018	Jan. 04, 2018	Jan. 15, 2020	Jan. 23, 2018
Subsequent Event [Member] | Unsecured Promissory Note [Member] | Chief Executive Officer [Member]
Debt Instrument, Face Amount				$ 500,000
Debt Instrument, Interest Rate, Stated Percentage				5.00%
Subsequent Event [Member] | Chief Medical Officer [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		280,000
Moncada [Member] | Scenario, Forecast [Member]
Consulting Agreement, Fee Amount Per Month	$ 25,000
Consulting Agreement, Additional Fee Amount			$ 40,000
Moncada [Member] | Subsequent Event [Member]
Consulting Agreement, Fee Amount upon Execution		$ 40,000